NCT04517357View on ClinicalTrials.gov

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

November 1, 2024

Conditions

Relapsed Ovarian Cancer

Interventions

DRUG

Fluzoparib+Apatinib

Fluzoparib-Apatinib combination

DRUG

Fluzoparib

Fluzoparib monotherapy

DRUG

Fluzoparib+Apatinib

Fluzoparib-Apatinib combination

Trial Locations (1)

310000

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04517357 - A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients | Biotech Hunter | Biotech Hunter